Summary

This report is an essential source for in-depth information and data relating to Republic of Korea IIn vitro diagnostic dvices market. It also offers detailed and comprehensive coverage of market revenue, distribution and company share information; and the latest news, financial deals and pipeline products information of each of the key sub-segments of the in vitro diagnostics market in Republic of Korea

Scope

-The report provides information on the Korean in vitro diagnostics market, broken down into detailed categories and segments such as In Vitro Diagnostics, Clinical Chemistry Test Reagents, Immunochemistry Test Reagents, Blood Test Reagents, Microbiology Test Reagents, Infectious Immunology, Test Reagents, Genetic Test Reagents, Self Testing, and Instruments.
-Total revenues, end users
-Market shares of all the key competitors.
-Key pipeline products that are set to shape the market, broken down by sector.
-Information on the top medical equipment companies in the sector in the country covering business description, strategic analysis.
-Healthcare structure, regulatory environment, approval process, pricing trends and reimbursement.
-Product and brand updates, strategy changes, R&D projects, corporate expansions and contractions and regulatory changes.
-Key mergers and acquisitions, partnerships, private equity investments and IPOs.
-Customer, hospitals and physicians data.

Reasons to buy

-Gain a strong understanding of the in vitro diagnostics devices market in Republic of Korea.
-Evaluate and compare the attractiveness of the market in the country.
-Identify growth segments and opportunities in each industry sector within the country.
-Evaluate the pipeline of key products that will change the sector, and identify threats and opportunities before the products are launched in the country.
-Analyze the competitiveness of the market in the country and identify hotspots.
-Develop strategies based on the latest product, brand, expansion and research and development news in the country.
-Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the market in the country.
-Identify and analyze the strengths and weaknesses of the industry incumbents in the country.

Table of Contents

1.1 List of Tables 10
1.2 List of Figures 13
2 Introduction 15
2.1 What Is This Report About? 15
3 Definitions of Markets Covered in This Report 16
3.1 In Vitro Diagnostics 16
3.2 Clinical Chemistry 16
3.2.1 Clinical Chemistry Rapid Tests & POC 16
3.2.2 Clinical Chemisty Analyzers 16
3.2.2.1 Automated Clinical Chemistry Analyzers 16
3.2.2.2 Semi-Automated Clinical Chemistry Analyzers 16
3.2.3 Electrolyte Chemistry Reagents 16
3.2.4 Enzyme Chemistry Reagents 17
3.2.5 Metabolite Chemistry Reagents 17
3.2.6 Urine Analysis 17
3.2.6.1 Urine Analyzer Reagents 17
3.2.6.2 Urine Analyzers 17
3.3 Genetic Testing 17
3.3.1 Acquired Gene or Chromosome Alterations 17
3.3.2 Inborn Gene or Chromosome Alterations 17
3.3.3 Other Genetic Tests 17
3.4 Haematology 17
3.4.1 Haematology Analyzers 17
3.4.2 Haematology Cell Counters 18
3.4.2.1 Differential Counters 18
3.4.2.2 Hemoglobinometers 18
3.4.3 Haematology Rapid Tests 18
3.4.3.1 Haemostasis Rapid Tests (Home Monitoring) 18
3.4.3.2 Rapid Haematology Tests (Point-Of-Care/Near Patient) 18
3.4.4 Haematology Reagents 18
3.4.4.1 Haematology Analyzer Reagents 18
3.4.4.2 Slide Stainers 18
3.4.5 Haemostasis 18
3.4.5.1 Coagulation Analyzers 18
3.4.5.2 Coagulation Factors 18
3.4.5.3 General Coagulation Tests 18
3.4.5.4 Platelet Factors 19
3.4.5.5 Special Coagulation Tests 19
3.4.6 Immunohaematology 19
3.4.6.1 ABO Typing 19
3.4.6.2 Antibody Detection 19
3.4.6.3 Rhesus Typing 19
3.5 Histology And Cytology 19
3.5.1 Cytology 19
3.5.1.1 Flow Cytometers 19
3.5.2 Histology 19
3.5.2.1 Monoclonal Antibodies 19
3.5.2.2 Tissue Typing Reagents 19
3.6 Immuno Chemistry 20
3.6.1 Disease Specific Immunochemistry 20
3.6.1.1 Auto-Immune Diseases 20
3.6.1.2 Cardiac Markers 20
3.6.1.3 Rheumatoid -Inflammatory Diseases Markers 20
3.6.1.4 Tumor markers 20
3.6.2 Drug Related Testing 20
3.6.2.1 Drugs of Abuse / Toxicology 20
3.6.2.2 Therapeutic Drug Monitoring 20
3.6.3 Endocrinology Tests 21
3.6.3.1 Fertility or Pregnancy Hormones 21
3.6.3.2 Individual and Specified Hormones 21
3.6.3.3 Thyroid Function Hormones 21
3.6.4 Immunochemistry Analyzers 21
3.6.4.1 Chemiluminescence Analyzers 21
3.6.4.2 ELISA Instruments 21
3.6.4.3 Immunofluorescence Analyzers 21
3.6.4.4 Radioimmunoassay Analyzers 21
3.6.5 Immunochemistry Rapid Tests 21
3.6.6 Organ Function Assays 21
3.6.7 Specific Proteins 22
3.7 Infectious Immunology 22
3.7.1 Bacteriology 22
3.7.2 Hepatitis Viruses 22
3.7.3 Other Virology 22
3.7.4 Retroviruses 22
3.8 Microbiology Culture 22
3.8.1 Bacterial Identification & Susceptibility Testing 22
3.8.2 Blood Culture 22
3.8.3 Immunological Culture Identification 22
3.8.4 Microbiology Analyzers 22
3.8.4.1 Automated Microbiology Analyzers 22
3.8.4.2 Semi-Automated Microbiology Analyzers 23
3.8.5 Mycobacteria Culture 23
3.8.6 Mycology Culture 23
3.8.7 Parasitology Culture 23
4 Healthcare Sector Review 24
4.1 Healthcare Expenditure 24
4.2 Healthcare Infrastructure 28
4.3 Healthcare Policy 32
5 Regulation System 33
5.1 Medical Equipment Approval Process 33
5.1.1 Classification 33
5.1.2 Premarket Notification for Class I Devices 34
5.1.3 Pre-market Approval for Class II, III and IV Devices 34
5.1.3.1 Technical Review: 34
5.1.3.2 Type Testing: 35
5.1.3.3 Applying for Product License: 35
5.1.3.4 KGMP Certification 35
5.1.4 License Fee 35
5.1.5 License Application Processing Duration 35
5.2 Post-market Surveillance 36
6 Pricing and Reimbursement 37
7 Distribution Structure 40
7.1 Distribution Structure 40
8 In Vitro Diagnostics In Republic of Korea 41
8.1 In Vitro Diagnostics, Republic of Korea, Overall Revenue ($ mn), 2000-2015 41
8.2 In Vitro Diagnostics, Republic of Korea, Company Share (2007-2008) 47
9 Clinical Chemistry In Republic of Korea 48
9.1 Clinical Chemistry Overall Revenue (2000-2015) 48
9.1.1 Clinical Chemistry Analyzers Revenue (2000-2015) 52
9.1.2 Urine Analysis Revenue (2000-2015) 54
9.2 Clinical Chemistry Distribution Share (2007-2008) 56
9.3 Clinical Chemistry, Republic of Korea, Company Share (2007-2008) 57
10 Genetic Testing In Republic of Korea 58
10.1 Genetic Testing Overall Revenue (2000-2015) 58
10.2 Genetic Testing Distribution Share (2007-2008) 60
10.3 Genetic Testing, Republic of Korea, Company Share (2007-2008) 61
11 Haematology In Republic of Korea 62
11.1 Haematology Overall Revenue (2000-2015) 62
11.1.1 Haematology Reagents Revenue (2000-2015) 66
11.1.2 Immunohaematology Revenue (2000-2015) 68
11.1.3 Haemostasis revenue (2000-2015) 70
11.1.4 Haematology Rapid Tests Revenue (2000-2015) 74
11.1.5 Haematology Cell Counters Revenue (2000-2015) 76
11.2 Haematology Distribution Share (2007-2008) 78
11.3 Haematology, Republic of Korea, Company Share (2007-2008) 79
12 Histology And Cytology In Republic of Korea 80
12.1 Histology And Cytology Overall Revenue (2000-2015) 80
12.1.1 Histology Revenue (2000-2015) 82
12.2 Histology And Cytology Distribution Share (2007-2008) 84
12.3 Histology And Cytology, Republic of Korea, Company Share (2007-2008) 85
13 Immuno Chemistry In Republic of Korea 86
13.1 Immuno Chemistry Overall Revenue (2000-2015) 86
13.1.1 Disease Specific Immunochemistry Revenue (2000-2015) 90
13.1.2 Drug Related Testing Revenue (2000-2015) 94
13.1.3 Endocrinology Tests Revenue (2000-2015) 96
13.1.4 Immunochemistry Analyzers Revenue (2000-2015) 98
13.2 Immuno Chemistry Distribution Share (2007-2008) 100
13.3 Immuno Chemistry, Republic of Korea, Company Share (2007-2008) 101
14 Infectious Immunology In Republic of Korea 103
14.1 Infectious Immunology Overall Revenue (2000-2015) 103
14.2 Infectious Immunology Distribution Share (2007-2008) 107
14.3 Infectious Immunology, Republic of Korea, Company Share (2007-2008) 108
15 Microbiology Culture In Republic of Korea 110
15.1 Microbiology Culture Overall Revenue (2000-2015) 110
15.1.1 Microbiology Analyzers Revenue (2000-2015) 114
15.2 Microbiology Culture Distribution Share (2007-2008) 116
15.3 Microbiology Culture, Republic of Korea, Company Share (2007-2008) 117
16 Overview of Key Companies in Republic of Korea In Vitro Diagnostics Market 118
16.1 F. Hoffmann-La Roche Ltd. 118
16.1.1 Company Overview 118
16.2 Siemens Healthcare 118
16.2.1 Company Overview 118
16.3 Sysmex Corporation 119
16.3.1 Company Overview 119
16.3.2 Sysmex Corporation Pipeline Products 119
16.3.2.1 Sysmex Corporation Pipeline Products By Equipment Type 119
16.3.2.2 Sysmex Corporation Pipeline Products By Development Stage 119
16.3.2.3 Sysmex Corporation Pipeline Products By Therapy Area 119
16.3.2.4 Sysmex Corporation Pipeline Products By News Summary 120
16.4 Abbott Laboratories 121
16.4.1 Company Overview 121
16.4.2 Abbott Laboratories Pipeline Products 121
16.4.2.1 Abbott Laboratories Pipeline Products By Equipment Type 121
16.4.2.2 Abbott Laboratories Pipeline Products By Development Stage 121
16.4.2.3 Abbott Laboratories Pipeline Products By Therapy Area 121
16.5 Beckman Coulter, Inc. 122
16.5.1 Company Overview 122
16.5.2 Beckman Coulter, Inc. Pipeline Products 123
16.5.2.1 Beckman Coulter, Inc. Pipeline Products By Equipment Type 123
16.5.2.2 Beckman Coulter, Inc. Pipeline Products By Development Stage 124
16.5.2.3 Beckman Coulter, Inc. Pipeline Products By Therapy Area 125
16.5.2.4 Beckman Coulter, Inc. Pipeline Products By News Summary 125
16.6 Ortho-Clinical Diagnostics Inc. 126
16.6.1 Company Overview 126
16.6.2 Ortho-Clinical Diagnostics Inc. Pipeline Products 126
16.6.2.1 Ortho-Clinical Diagnostics Inc. Pipeline Products By Equipment Type 126
16.6.2.2 Ortho-Clinical Diagnostics Inc. Pipeline Products By Development Stage 127
16.6.2.3 Ortho-Clinical Diagnostics Inc. Pipeline Products By Therapy Area 127
16.7 OLYMPUS CORPORATION 128
16.7.1 Company Overview 128
16.8 Qiagen N.V. 128
16.8.1 Company Overview 128
16.9 bioMerieux S.A. 129
16.9.1 Company Overview 129
16.10 Bio-Rad Laboratories, Inc. 129
16.10.1 Company Overview 129
16.11 Phadia AB 130
16.11.1 Company Overview 130
16.11.2 Phadia AB Pipeline Products 130
16.11.2.1 Phadia AB Pipeline Products By Equipment Type 130
16.11.2.2 Phadia AB Pipeline Products By Development Stage 130
16.11.2.3 Phadia AB Pipeline Products By Therapy Area 131
16.11.2.4 Phadia AB Pipeline Products By News Summary 131
16.12 DiaSorin S.p.A 132
16.12.1 Company Overview 132
16.12.2 DiaSorin S.p.A Pipeline Products 132
16.12.2.1 DiaSorin S.p.A Pipeline Products By Equipment Type 132
16.12.2.2 DiaSorin S.p.A Pipeline Products By Development Stage 132
16.12.2.3 DiaSorin S.p.A Pipeline Products By Therapy Area 132
16.13 Becton, Dickinson and Company 133
16.13.1 Company Overview 133
16.14 Gen-Probe Incorporated 134
16.14.1 Company Overview 134
16.14.2 Gen-Probe Incorporated Pipeline Products 134
16.14.2.1 Gen-Probe Incorporated Pipeline Products By Equipment Type 134
16.14.2.2 Gen-Probe Incorporated Pipeline Products By Development Stage 135
16.14.2.3 Gen-Probe Incorporated Pipeline Products By Therapy Area 135
16.14.2.4 Gen-Probe Incorporated Pipeline Products By Clinical Trials 135
16.14.2.5 Gen-Probe Incorporated Pipeline Products By News Summary 136
16.15 Inverness Medical Innovations, Inc. 137
16.15.1 Company Overview 137
16.15.2 Inverness Medical Innovations, Inc. Pipeline Products 137
16.15.2.1 Inverness Medical Innovations, Inc. Pipeline Products By Equipment Type 137
16.15.2.2 Inverness Medical Innovations, Inc. Pipeline Products By Development Stage 138
16.15.2.3 Inverness Medical Innovations, Inc. Pipeline Products By Therapy Area 138
16.15.2.4 Inverness Medical Innovations, Inc. Pipeline Products By Clinical Trials 138
16.15.2.5 Inverness Medical Innovations, Inc. Pipeline Products By News Summary 139
16.16 Mindray Medical International Limited 140
16.16.1 Company Overview 140
16.17 Boditech Med Inc. 140
16.17.1 Company Overview 140
16.18 Roche Diagnostics Korea Co., Ltd. 140
16.18.1 Company Overview 140
17 Financial Deals Landscape 141
17.1 Partnerships 141
17.1.1 DxS Signs Cross-Licensing Agreement with Epigenomics 141
17.1.2 Prodesse Enters Into A licensing Agreement With Abbott Laboratories 142
17.1.3 Seegene Enters Into An Agreement With Randox Laboratories 143
18 Recent Developments 144
18.1 Product News 144
18.1.1 Apr 29, 2009: Seegene Launches Seeplex Diarrhea ACE Detection Test 144
18.1.2 Mar 03, 2009: Seegene Announces The Launch Of Seeplex MTB ACE Detection Test 144
19 Appendix 145
19.1  Research Methodology 145
19.2 Secondary Research 146
19.3 Primary Research 146
19.4 Models 147
19.5 Forecasts 147
19.6 Expert Panel Validation 147
19.7 Currency Conversion 148
19.8 Contact Us 149
19.9 Disclaimer 149

1.1 List of Tables
Table 1: Total Healthcare Expenditure, Republic of Korea, 2000 ¨C 2007 25
Table 2: Hospital Wards by Specialty in Republic of Korea, 2003-2007 29
Table 3: Doctors by Specialty in Republic of Korea, 2003-2007 30
Table 4: Healthcare Institutions in Republic of Korea, 2001-2005 31
Table 5: Healthcare Personnel in Republic of Korea, 1975-2002 31
Table 6: Classification of Medical Equipment in Republic of Korea 33
Table 7:In Vitro Diagnostics, Republic of Korea, Overall Revenue ($ mn), 2000-2015 41
Table 8: In Vitro Diagnostics, Republic of Korea, Cross-Category Analysis, 2000-2015 42
Table 9:In Vitro Diagnostics, Republic of Korea, Overall Revenue ($ mn), Historic, 2000-2008 44
Table 10:In Vitro Diagnostics, Republic of Korea, Overall Revenue ($ mn), Forecast, 2008-2015 46
Table 11:In Vitro Diagnostics, Republic of Korea, Company Share by Revenue ($ mn), 2007-2008 47
Table 12:Clinical Chemistry, Republic of Korea, Revenue ($ mn) by Segment, Historic, 2000-2008 49
Table 13:Clinical Chemistry, Republic of Korea, Revenue ($ mn) by Segment, Forecast, 2008-2015 51
Table 14:Clinical Chemistry Analyzers, Republic of Korea, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 52
Table 15:Clinical Chemistry Analyzers, Republic of Korea, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 53
Table 16:Urine Analysis, Republic of Korea, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 54
Table 17:Urine Analysis, Republic of Korea, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 55
Table 18:Clinical Chemistry, Republic of Korea, Distribution Share by Revenue ($mn), 2007-2008 56
Table 19:Clinical Chemistry, Republic of Korea, Company Share by Revenue ($ mn), 2007-2008 57
Table 20:Genetic Testing, Republic of Korea, Revenue ($ mn) by Segment, Historic, 2000-2008 58
Table 21:Genetic Testing, Republic of Korea, Revenue ($ mn) by Segment, Forecast, 2008-2015 59
Table 22:Genetic Testing, Republic of Korea, Distribution Share by Revenue ($mn), 2007-2008 60
Table 23:Genetic Testing, Republic of Korea, Company Share by Revenue ($ mn), 2007-2008 61
Table 24:Haematology, Republic of Korea, Revenue ($ mn) by Segment, Historic, 2000-2008 63
Table 25:Haematology, Republic of Korea, Revenue ($ mn) by Segment, Forecast, 2008-2015 65
Table 26:Haematology Reagents, Republic of Korea, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 66
Table 27:Haematology Reagents, Republic of Korea, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 67
Table 28:Immunohaematology, Republic of Korea, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 68
Table 29:Immunohaematology, Republic of Korea, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 69
Table 30:Haemostasis, Republic of Korea, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 71
Table 31:Haemostasis, Republic of Korea, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 73
Table 32:Haematology Rapid Tests, Republic of Korea, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 74
Table 33:Haematology Rapid Tests, Republic of Korea, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 75
Table 34:Haematology Cell Counters, Republic of Korea, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 76
Table 35:Haematology Cell Counters, Republic of Korea, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 77
Table 36:Haematology, Republic of Korea, Distribution Share by Revenue ($mn), 2007-2008 78
Table 37:Haematology, Republic of Korea, Company Share by Revenue ($ mn), 2007-2008 79
Table 38:Histology And Cytology, Republic of Korea, Revenue ($ mn) by Segment, Historic, 2000-2008 80
Table 39:Histology And Cytology, Republic of Korea, Revenue ($ mn) by Segment, Forecast, 2008-2015 81
Table 40:Histology, Republic of Korea, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 82
Table 41:Histology, Republic of Korea, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 83
Table 42:Histology And Cytology, Republic of Korea, Distribution Share by Revenue ($mn), 2007-2008 84
Table 43:Histology And Cytology, Republic of Korea, Company Share by Revenue ($ mn), 2007-2008 85
Table 44:Immuno Chemistry, Republic of Korea, Revenue ($ mn) by Segment, Historic, 2000-2008 87
Table 45:Immuno Chemistry, Republic of Korea, Revenue ($ mn) by Segment, Forecast, 2008-2015 89
Table 46:Disease Specific Immunochemistry, Republic of Korea, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 91
Table 47:Disease Specific Immunochemistry, Republic of Korea, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 93
Table 48:Drug Related Testing, Republic of Korea, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 94
Table 49:Drug Related Testing, Republic of Korea, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 95
Table 50:Endocrinology Tests, Republic of Korea, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 96
Table 51:Endocrinology Tests, Republic of Korea, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 97
Table 52:Immunochemistry Analyzers, Republic of Korea, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 98
Table 53:Immunochemistry Analyzers, Republic of Korea, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 99
Table 54:Immuno Chemistry, Republic of Korea, Distribution Share by Revenue ($mn), 2007-2008 100
Table 55:Immuno Chemistry, Republic of Korea, Company Share by Revenue ($ mn), 2007-2008 102
Table 56:Infectious Immunology, Republic of Korea, Revenue ($ mn) by Segment, Historic, 2000-2008 104
Table 57:Infectious Immunology, Republic of Korea, Revenue ($ mn) by Segment, Forecast, 2008-2015 106
Table 58:Infectious Immunology, Republic of Korea, Distribution Share by Revenue ($mn), 2007-2008 107
Table 59:Infectious Immunology, Republic of Korea, Company Share by Revenue ($ mn), 2007-2008 109
Table 60:Microbiology Culture, Republic of Korea, Revenue ($ mn) by Segment, Historic, 2000-2008 111
Table 61:Microbiology Culture, Republic of Korea, Revenue ($ mn) by Segment, Forecast, 2008-2015 113
Table 62:Microbiology Analyzers, Republic of Korea, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 114
Table 63:Microbiology Analyzers, Republic of Korea, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 115
Table 64:Microbiology Culture, Republic of Korea, Distribution Share by Revenue ($mn), 2007-2008 116
Table 65:Microbiology Culture, Republic of Korea, Company Share by Revenue ($ mn), 2007-2008 117
Table 66:Sysmex Corporation Pipeline Products by Equipment Type 119
Table 67:Sysmex Corporation Pipeline Products By Development Stage 119
Table 68:Sysmex Corporation Pipeline Products By Therapy Area 119
Table 69:Sysmex Corporation Pipeline Products By News Summary 120
Table 70:Abbott  Laboratories Pipeline Products by Equipment Type 121
Table 71:Abbott  Laboratories Pipeline Products By Development Stage 121
Table 72:Abbott  Laboratories Pipeline Products By Therapy Area 121
Table 73:Beckman Coulter, Inc. Pipeline Products by Equipment Type 123
Table 74:Beckman Coulter, Inc. Pipeline Products By Development Stage 124
Table 75:Beckman Coulter, Inc. Pipeline Products By Therapy Area 125
Table 76:Beckman Coulter, Inc. Pipeline Products By News Summary 125
Table 77:Ortho-Clinical Diagnostics Inc. Pipeline Products by Equipment Type 126
Table 78:Ortho-Clinical Diagnostics Inc. Pipeline Products By Development Stage 127
Table 79:Ortho-Clinical Diagnostics Inc. Pipeline Products By Therapy Area 127
Table 80:Phadia AB Pipeline Products by Equipment Type 130
Table 81:Phadia AB Pipeline Products By Development Stage 130
Table 82:Phadia AB Pipeline Products By Therapy Area 131
Table 83:Phadia AB Pipeline Products By News Summary 131
Table 84:DiaSorin S.p.A Pipeline Products by Equipment Type 132
Table 85:DiaSorin S.p.A Pipeline Products By Development Stage 132
Table 86:DiaSorin S.p.A Pipeline Products By Therapy Area 132
Table 87:Gen-Probe Incorporated Pipeline Products by Equipment Type 134
Table 88:Gen-Probe Incorporated Pipeline Products By Development Stage 135
Table 89:Gen-Probe Incorporated Pipeline Products By Therapy Area 135
Table 90:Gen-Probe Incorporated Pipeline Products By Clinical Trials 135
Table 91:Gen-Probe Incorporated Pipeline Products By News Summary 136
Table 92:Inverness Medical Innovations, Inc. Pipeline Products by Equipment Type 137
Table 93:Inverness Medical Innovations, Inc. Pipeline Products By Development Stage 138
Table 94:Inverness Medical Innovations, Inc. Pipeline Products By Therapy Area 138
Table 95:Inverness Medical Innovations, Inc. Pipeline Products By Clinical Trials 138
Table 96:Inverness Medical Innovations, Inc. Pipeline Products By News Summary 139
Table 97:DxS Signs Cross-Licensing Agreement With Epigenomics 141
Table 98:Prodesse Enters Into A licensing Agreement With Abbott Laboratories 142
Table 99:Seegene Enters Into An Agreement With Randox Laboratories 143
Table 100:   USD to Local Currency, Average Exchange Rate 2008 148

1.2 List of Figures
Figure 1: Total Healthcare Expenditure, Republic of Korea, 2000 ¨C 2007 25
Figure 2: Government and Private Healthcare Expenditure in Republic of Korea, 2007 26
Figure 3: Healthcare Financing in Republic of Korea, 2007 27
Figure 4: Evaluation (Value Appraisal) Criteria for Medical Device Reimbursement in Republic of Korea, 2007 38
Figure 5: Medical Device Pricing System in Republic of Korea, 2007 39
Figure 6:In Vitro Diagnostics, Republic of Korea, Overall Revenue ($ mn), 2000-2015 41
Figure 7:     In Vitro Diagnostics, Republic of Korea, Cross-Category Analysis, 2000-2015 42
Figure 8:In Vitro Diagnostics, Republic of Korea, Overall Revenue ($ mn), Historic, 2000-2008 43
Figure 9:In Vitro Diagnostics, Republic of Korea, Overall Revenue ($ mn), Forecast, 2008-2015 45
Figure 10:In Vitro Diagnostics, Republic of Korea, Company Share (%), 2008 47
Figure 11:Clinical Chemistry, Republic of Korea, Revenue ($ mn) by Segment, Historic, 2000-2008 48
Figure 12:Clinical Chemistry, Republic of Korea, Revenue ($ mn) by Segment, Forecast, 2008-2015 50
Figure 13:Clinical Chemistry Analyzers, Republic of Korea, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 52
Figure 14:Clinical Chemistry Analyzers, Republic of Korea, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 53
Figure 15:Urine Analysis, Republic of Korea, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 54
Figure 16:Urine Analysis, Republic of Korea, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 55
Figure 17:Clinical Chemistry, Republic of Korea, Company Share (%), 2008 57
Figure 18:Genetic Testing, Republic of Korea, Revenue ($ mn) by Segment, Historic, 2000-2008 58
Figure 19:Genetic Testing, Republic of Korea, Revenue ($ mn) by Segment, Forecast, 2008-2015 59
Figure 20:Genetic Testing, Republic of Korea, Company Share (%), 2008 61
Figure 21:Haematology, Republic of Korea, Revenue ($ mn) by Segment, Historic, 2000-2008 62
Figure 22:Haematology, Republic of Korea, Revenue ($ mn) by Segment, Forecast, 2008-2015 64
Figure 23:Haematology Reagents, Republic of Korea, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 66
Figure 24:Haematology Reagents, Republic of Korea, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 67
Figure 25:Immunohaematology, Republic of Korea, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 68
Figure 26:Immunohaematology, Republic of Korea, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 69
Figure 27:Haemostasis, Republic of Korea, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 70
Figure 28:Haemostasis, Republic of Korea, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 72
Figure 29:Haematology Rapid Tests, Republic of Korea, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 74
Figure 30:Haematology Rapid Tests, Republic of Korea, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 75
Figure 31:Haematology Cell Counters, Republic of Korea, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 76
Figure 32:Haematology Cell Counters, Republic of Korea, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 77
Figure 33:Haematology, Republic of Korea, Company Share (%), 2008 79
Figure 34:Histology And Cytology, Republic of Korea, Revenue ($ mn) by Segment, Historic, 2000-2008 80
Figure 35:Histology And Cytology, Republic of Korea, Revenue ($ mn) by Segment, Forecast, 2008-2015 81
Figure 36:Histology, Republic of Korea, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 82
Figure 37:Histology, Republic of Korea, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 83
Figure 38:Histology And Cytology, Republic of Korea, Company Share (%), 2008 85
Figure 39:Immuno Chemistry, Republic of Korea, Revenue ($ mn) by Segment, Historic, 2000-2008 86
Figure 40:Immuno Chemistry, Republic of Korea, Revenue ($ mn) by Segment, Forecast, 2008-2015 88
Figure 41:Disease Specific Immunochemistry, Republic of Korea, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 90
Figure 42:Disease Specific Immunochemistry, Republic of Korea, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 92
Figure 43:Drug Related Testing, Republic of Korea, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 94
Figure 44:Drug Related Testing, Republic of Korea, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 95
Figure 45:Endocrinology Tests, Republic of Korea, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 96
Figure 46:Endocrinology Tests, Republic of Korea, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 97
Figure 47:Immunochemistry Analyzers, Republic of Korea, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 98
Figure 48:Immunochemistry Analyzers, Republic of Korea, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 99
Figure 49:Immuno Chemistry, Republic of Korea, Company Share (%), 2008 101
Figure 50:Infectious Immunology, Republic of Korea, Revenue ($ mn) by Segment, Historic, 2000-2008 103
Figure 51:Infectious Immunology, Republic of Korea, Revenue ($ mn) by Segment, Forecast, 2008-2015 105
Figure 52:Infectious Immunology, Republic of Korea, Company Share (%), 2008 108
Figure 53:Microbiology Culture, Republic of Korea, Revenue ($ mn) by Segment, Historic, 2000-2008 110
Figure 54:Microbiology Culture, Republic of Korea, Revenue ($ mn) by Segment, Forecast, 2008-2015 112
Figure 55:Microbiology Analyzers, Republic of Korea, Revenue ($ mn) by Sub-Segment, Historic, 2000-2008 114
Figure 56:Microbiology Analyzers, Republic of Korea, Revenue ($ mn) by Sub-Segment, Forecast, 2008-2015 115
Figure 57:Microbiology Culture, Republic of Korea, Company Share (%), 2008 117
Figure 58: Methodology 145